Navigation Links
TGen finds therapeutic targets for rare cancer in children
Date:9/1/2010

PHOENIX, Ariz. Aug. 31, 2010 The first study of Ewing's sarcoma that screened hundreds of genes based on how they affect cell growth has identified two potential anti-cancer drug targets, according to a scientific paper by the Translational Genomics Research Institute (TGen) published this month in the journal Molecular Cancer.

Ewing's sarcomas are rare, but aggressive cancer lesions that occur most frequently in the bones of teenagers. They represent nearly 3 percent of all childhood cancers. Patients are treated with a combination of surgery, radiation and chemotherapy. This cancer can reoccur after surgical removal, and often spreads to the lungs, other bones and bone marrow. Once it spreads, or metastasizes, only 1 in 5 patients survive more than 5 years.

These lesions harbor unique chromosomal abnormalities that give rise to fusion genes that act as cancer-inducing proteins, or oncoproteins.

TGen researchers used RNAi-based phenotypic, or loss-of-function screening, a method of silencing hundreds of individual genes in a high-throughput format, to analyze 572 kinases that are expressed in human cells. Kinases are enzymes that modify other proteins. Using this technique, the authors discovered two protein kinases with important roles in the growth and survival of Ewing's sarcoma cells. Cancer cells died when investigators stopped the normal function of the two protein kinases called STK10 and TNK2.

"RNAi-based phenotypic profiling proved to be a powerful gene target discovery strategy, leading to successful identification and validation of STK10 and TNK2 as two novel potential therapeutic targets for Ewing's sarcoma," said Dr. David Azorsa, a TGen Senior Investigator and the paper's senior author.

This was the first study demonstrating the use of this kind of phenotypic profiling to identify unique kinase targets for Ewing's sarcoma, according to the paper.

By identifying kinases that regulate the growth of Ewing's sarcoma cells, TGen investigators anticipate a rapid translation of their discoveries into clinical drug trials and specific remedies for individual patients, advancing the prospects of personalized medicine.

"We undertook this study with the goal of identifying specific kinases that can be targeted to modulate Ewing's sarcoma cell growth and survival," said Dr. Shilpi Arora, a TGen Staff Scientist and the paper's lead author. "In addition to the identification of specific kinase targets, we were able to obtain a better understanding of contextual vulnerabilities in Ewing's sarcoma."


'/>"/>

Contact: Steve Yozwiak
syozwiak@tgen.org
602-343-8704
The Translational Genomics Research Institute
Source:Eurekalert

Related medicine news :

1. Study finds an increased risk of death in men with insomnia and a short sleep duration
2. FDA Finds Rodents, Manure Piles at Farms in Egg Recall
3. Study finds asking about pregnancy coercion and intimate-partner violence can reduce their incidence
4. Location determines social network influence, CCNY-led team finds
5. Herpes Drugs Wont Raise Birth Defect Risk, Study Finds
6. Mumps vaccine coverage should be improved, study finds
7. Survey of American women finds STD vaccine viewed positively
8. Study Finds Even a Little Cigarette Smoke Harms Airway
9. New study finds new connection between yoga and mood
10. Global media campaign finds hidden children with rare, fatal aging disorder
11. VCU Massey research finds new link between inflammation and cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... ... April 24, 2017 , ... The world-class ... support to bring their novel lifesaving device for the everyday use of parents ... sensors, specially designed to read a child’s vital signs, and detect unusual symptoms ...
(Date:4/24/2017)... Ill., and Waycross, Ga. (PRWEB) , ... April ... ... market leader and trusted advisor within the telehealth industry, announces the company’s VideoMedicine ... U.S. board-certified primary care providers. Available 24 hours a day, Quick Care provides ...
(Date:4/24/2017)... ... April 24, 2017 , ... According ... overdose deaths now claim the lives of 62 Americans each day.(1) Yet since ... drug manufacturers, distributors, pharmacies and prescribers by more than half.(2) Novus Medical ...
(Date:4/24/2017)... ... April 24, 2017 , ... ... recognize elevated anxiety levels in people with addiction who are served by MAP’s ... a biosensing wearable device that monitors heart and breath rates to identify anxiety ...
(Date:4/24/2017)... ... 2017 , ... Pitavastatin, a relatively new statin, has relevance ... to have significant interactions with antiretroviral therapy (ART). Among people living with ... inflammation in the bloodstream. , While lowering cholesterol and dampening inflammation are beneficial ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... April 20, 2017 NeuroVive Pharmaceutical AB ... announced positive preclinical results demonstrating anti-fibrotic effects ... non-alcoholic steatohepatitis (NASH), in an additional well-validated ... NV556 has previously shown similar anti-fibrotic effects ... NeuroVive,s scientists present novel data demonstrating anti-fibrotic ...
(Date:4/19/2017)...  IRIDEX Corporation (Nasdaq: IRIX ) today ... first quarter 2017 after the close of trading on ... host a corresponding conference call beginning at 2:30 p.m. ... in listening to the conference call may do so ... 326-3030 for international callers, using conference ID: 92158987.  A ...
(Date:4/19/2017)... 19, 2017  Sorrento Therapeutics, Inc. (NASDAQ: ... company developing new treatments for cancer and other ... its previously announced underwritten public offering of 23,625,084 ... offering price of $2.00 per share, before deducting ... payable by Sorrento.  The net proceeds to Sorrento ...
Breaking Medicine Technology: